Söndag 22 December | 07:11:26 Europe / Stockholm

Kalender

Tid*
2025-05-06 N/A Årsstämma
2025-02-12 12:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2022-06-30 11:30:36

Olife will participate in the biennial National PKU Alliance, NPKUA, in Vancouver, Washington, USA on July 7-10, 2022, with a poster presentation as well as take part in a discussion panel on home monitoring of PHE levels.

The National PKU Alliance (NPKUA) is the largest event for the PKU community in the world and brings together patients, relatives, industry, and research partners every two years. This year, Qlife takes part in the conference, presenting a poster: "A Novel Home Monitoring Platform for Quantitative Determination of Phenylalanine in Phenylketonuria Patients", and takes part in the discussion panel "When Can I Test Blood at Home? An Update on the Home Phe Monitor Panel

Discussion". Julie Hindkaer, Assay Development, will be representing Qlife.

"Being present at NPKUA gives Qlife an opportunity to listen, learn and broaden our network as well as to present Egoo PHE test to the largest PKU community in the world", says Thomas Warthoe, CEO of Qlife

Phenylketonuria, also called PKU, is a rare inherited disorder that causes an amino acid called phenylalanine to build up in the body. PKU is caused by a change in the phenylalanine hydroxylase (PAH) gene. This gene helps create the enzyme needed to break down phenylalanine.

Without the enzyme necessary to break down phenylalanine, a dangerous buildup can develop when a person with PKU eats foods that contain protein (phenylalanine source) or eats aspartame, an artificial sweetener. This can eventually lead to serious health problems.

The treatment is a lifelong diet. As first in the world, the Egoo PHE test makes it possible to monitor PHE (Phenylalanine) levels each day from home daily.